Abstract
The simultaneous administration of several chemotherapeutic agents individually active against a particular neoplasm has become a major therapeutic principle in clinical oncology. The advantages of such an approach include the ability to administer drugs which are potentially non-cross resistant and which demonstrate non-overlapping toxicities. It has been hypothesized that the administration of combination chemotherapy will help prevent the emergence of a multiply resistant cell line to which all antineoplastic agents are inactive (1). The success of combination chemotherapy in increasing the complete remission rate, prolonging survival and curing a significant percentage of patients with childhood acute lymphoblastic leukemia, Hodgkin’s disease, diffuse histiocytic lymphoma and testicular carcinoma attests to the soundness of the basic principles of multi-agent chemotherapy. In addition, in certain other malignancies where the cure rate remains poor, significant palliation of symptoms and prolongation of survival can be achieved through the use of combination chemotherapy.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Goldie JH, Coldman AJ: A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63: 1727–1733, 1979.
Dedrick RL, Myers CE, Bungay PM, DeVita VT Jr: Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62: 1–9, 1978.
Howell SB, Pfeifle CE, Wung WE, Olshen RA, Lucas WE, Yon JL, Green MR: Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 97: 845–851, 1982.
Pfeifle CE, King ME, Howell SB: Pharmacokinetics and clinical efficacy of intraperitoneal cytarabine treatment of advanced ovarian cancer. Proc Am Soc Clin Oncol 2: 150, 1983.
Ozols RF, Young RC, Speyer JL, Sugarbaker PH, Green R., Jenkins J, Myers CE: Phase I and pharmacological studies of Adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer 42: 4265–4269, 1982.
Speyer JL, Collins JM, Dedrick RL, Brennan MF, Buckpitt AR, Londer H, DeVita VT Jr, Myers CE: Phase I pharmacological studies of 5-fluorouracil administered intraperitoneally. Cancer Res 40: 567–572, 1980.
Pfeifle CE, Howell SB, Olshen RA, Wung WE: Intraperitoneal melphalan: A phase I study. Am Soc Clin Pharm Therap 33: 223, 1983.
Howell SB, Chu BCF, Wung WE, Metha BM, Mendelsohn J: Long-duration intracavitary infusion of methotrexate with systemic leucovorin protection in patients with malignant effusions. J Clin Invest 67: 1161–1170, 1981.
Jones RB, Collins JM, Myers CE, Brooks AS, Hubbard SM, Balow JE, Brennan MR, Dedrick RL, DeVita VT Jr: High-volume intraperitoneal chemotherapy with methotrexate in patients with cancer. Cancer Res 41: 55–59, 1981.
Gyves J, Ensminger W, Niederhuber J, Manuzak P, Van Harken D, Janis MA, Stetson P, Knutsen C, Doan K: Phase I study of intraperitoneal (IP) 5 day continuous 5-FU infusion and bolus mitomycin C. Proc Am Soc Clin Oncol 1: 15, 1982.
Katz ME, Schwartz PE, Kapp DS, Luikart S: Epithelial carcinoma of the ovary: current strategies. Ann Intern Med 95: 98–111, 1981.
Williams CJ, Mead B, Arnold A, Green J, Buchanan R, Whitehouse M: Chemotherapy of advanced ovarian carcinoma: initial experience using a platinum-based combination. Cancer 49: 1178–1783, 1982.
Cohen CJ, Goldberg JD, Holland JF, Bruckner HW, Deppe B, Gusberg SB, Wallach RC, Kabakow B, Rodin J: Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO stages III and IV) as measured by surgical end-staging (second-look operation). Am J Obstet Gynecol 145: 955–967, 1983.
Wasserman TH, Comis RL, Goldsmith M, Handelsman H, Penta JS, Slavik M, Soper WP, Carter SK: Tabular analysis of the clinical chemotherapy of solid tumors. Cancer Chemother Rep 6 (3): 399–419, 1975.
Bergerat J-P, Green C, Drewinko B: Combination chemotherapy in vitro. IV. response of human colon carcinoma cells to combinations using cis-diamminedichloroplatinum. Cancer Biochem Biophy 3: 173–180, 1979.
Bergerat J-P, Drewinko B, Corry P, Barlogie B, Ho DH: Synergistic lethal effect of cis-dichlorodiammineplatinum and 1-Beta-D-arabinofuranosylcytosine. Cancer Res 41: 25–30, 1981.
Antman KH: Malignant mesothelioma. N Engl J Med 303:200Bethesda202, 1980.
Aisner J, Wiernik PH: Chemotherapy in the treatment of malignant mesothelioma. Sem Oncol 8: 335–343, 1981.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1984 Martinus Nijhoff Publishers, Boston
About this chapter
Cite this chapter
Markman, M. (1984). Combination Cisplatin-Based Intracavitary Chemotherapy. In: Howell, S.B. (eds) Intra-Arterial and Intracavitary Cancer Chemotherapy. Developments in Oncology, vol 26. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-3843-7_18
Download citation
DOI: https://doi.org/10.1007/978-1-4613-3843-7_18
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-3845-1
Online ISBN: 978-1-4613-3843-7
eBook Packages: Springer Book Archive